Page 3 - Strides Pharma Science

Strides Pharma posts threefold rise in profit-before-tax at Rs 103.6 crore

The Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year

Strides Pharma Science may resume Ranitidine drug sale in US market

Strides' Ranitidine tablets 300 mg is within the acceptable limits for N-nitrosodimethylamine (NDMA) of 96 nanograms per day or 0.32 ppm

Strides Pharma likely to launch affordable insulin from Stelis stable

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability.

Strides Pharma resumes sales of antacid drug Ranitidine in Australia

Strides predominantly sells Ranitidine tablets in the US markets

Strides Pharma dips 6% after it temporarily suspends Ranitidine sales in US

The stock of pharmaceuticals company was trading lower for the fifth straight day, slipping 14 per cent, as against a 2 per cent rise in the benchmark S&P BSE Sensex during the week.

Strides Pharma soars 12% after Co announces JV with Chinese firm

Strides Pharma Global Pte (Singapore) and Sun Moral International (Hong Kong), a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings, have entered into a JV to form called Sihuan Strides.

USFDA finds adulteration, 'significant violations' at Strides Pharma plant

The regulator found 'significant violations' of current good manufacturing practice regulations at Strides Pharma's plant in Puducherry

Strides Pharma Puducherry unit receives warning letter from USFDA

The drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.

Strides Pharma Science's arm gets USFDA nod to market laxative drug in US

The product will be manufactured at Strides' facility in Bengaluru and will be marketed by Strides Pharma in the US market